Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Oct 16, 2025, 17:31 ET

      Share this article

      Share this article


      The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch of therapies such as AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat (Xynomic Pharmaceuticals), ZE50-0134 (Eilean Therapeutics), NVG-111 (NovalGen), and others will further fuel the market.

      LAS VEGAS, Oct. 16, 2025 /PRNewswire/ -- DelveInsight's Indolent Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, indolent lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

      Indolent Lymphoma Market Summary

      • The market size for indolent lymphoma in the leading markets is expected to grow significantly by 2034.
      • The United States accounted for the highest indolent lymphoma treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
      • Indolent lymphoma accounts for 41% of all NHL cases in North America and Northern Europe.
      • Leading indolent lymphoma companies developing emerging therapies, such as AstraZeneca, BeiGene, Xynomic Pharmaceuticals, Enterome, NovalGen, Eilean Therapeutics, and others, are developing new therapy for indolent lymphoma that can be available in the indolent lymphoma market in the coming years.
      • The promising indolent lymphoma therapies in clinical trials include AZD0486, BGB-16673, Sonrotoclax + Zanubrutinib, Abexinostat, EO2463, NVG-111, ZE50-0134, and others.

      Discover the indolent lymphoma new treatment @ New Treatments for Indolent Lymphoma

      Key Factors Driving the Growth of the Indolent Lymphoma Market

      Advancements in Targeted and Immunotherapy Treatments

      The development of novel therapies, including oral and injectable medications, has improved the management of indolent lymphoma. These treatments offer greater efficacy, reduced side effects, and more precise mechanisms, leading to enhanced patient outcomes and satisfaction.

      Technological Innovations in Molecular Profiling

      Advancements in molecular profiling techniques, such as next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis, have enabled the identification of genetic alterations contributing to disease development and progression. These technologies guide targeted treatment approaches, improving therapeutic outcomes.

      Rising Indolent Lymphoma Clinical Trial Activity

      Several potential therapies are being investigated for the management of indolent lymphoma. The anticipated launch of the promising candidate like AZD0486, EO2463, Abexinostat, CTX112, Docirbrutinib, NVG-111, and others during the forecast period (2025–2034) is expected to bring about a significant shift in the market dynamics of indolent lymphoma.

      Indolent Lymphoma Market Analysis

      The management of indolent lymphoma, a slow-growing form of non-Hodgkin lymphoma, has advanced considerably, providing a variety of treatment options tailored to disease stage, symptom burden, and patient health. For early-stage or asymptomatic patients, a "watch and wait" strategy is often recommended, as immediate therapy may not improve outcomes. When treatment becomes necessary, monoclonal antibodies are the standard first-line option, either alone or combined with chemotherapy regimens such as bendamustine, CHOP, or CVP.

      For relapsed or refractory cases, targeted therapies play a central role, including BTK inhibitors (e.g., ibrutinib, zanubrutinib), PI3K inhibitors (e.g., copanlisib, duvelisib, umbralisib), and EZH2 inhibitors like tazemetostat, particularly in EZH2-mutated follicular lymphoma. In more advanced disease, CAR T-cell therapies (e.g., axi-cel, liso-cel) and bispecific antibodies such as epcoritamab and mosunetuzumab have demonstrated high response rates in both clinical trials and real-world settings. Other approaches, including radioimmunotherapy and autologous stem cell transplantation, may be appropriate for selected patients. Active research into immunotherapies and precision medicine continues to broaden treatment possibilities, aiming to achieve deeper, longer-lasting remissions with reduced toxicity.

      To know more about indolent lymphoma treatment options, visit @ Approved Indolent Lymphoma Drugs

      Indolent Lymphoma Competitive Landscape

      Several potential therapies are being investigated for the management of indolent lymphoma. The anticipated launch of the promising candidate like AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat (Xynomic Pharmaceuticals), ZE50-0134 (Eilean Therapeutics), NVG-111 (NovalGen), and others during the forecast period (2025–2034) is expected to bring about a significant shift in the market dynamics of indolent lymphoma.

      AstraZeneca's AZD0486 (previously TNB-486) is a next-generation, fully human IgG4 CD19xCD3 bispecific T-cell engager (TCE) that features a unique low-affinity anti-CD3 component. This design aims to minimize cytokine release while maintaining strong T-cell–mediated killing of malignant B cells. Its silenced Fc region prevents nonspecific interactions and antibody-dependent cellular cytotoxicity, and provides a prolonged half-life that supports intermittent dosing.

      Enterome's EO2463 is a novel, off-the-shelf OncoMimics active immunotherapy composed of four synthetic peptides. These microbial-derived, non-self peptides mimic CD8 HLA-A2 epitopes that resemble B cell–specific markers CD20, CD22, CD37, and CD268 (BAFF receptor). The therapy also incorporates a CD4+ helper peptide, universal cancer peptide 2 (UCP2), to enhance immune activation.

      The anticipated launch of these emerging therapies are poised to transform the indolent lymphoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the indolent lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about therapy for indolent lymphoma @ Indolent Lymphoma Clinical Trials

      Recent Developments in the Indolent Lymphoma Market

      • In August 2025, Bristol Myers Squibb announced FDA has accepted the supplemental biologics license application (sBLA) for BREYANZI (lisocabtagene maraleucel) as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
      • In June 2025, Enterome presented positive interim results for its OncoMimic immunotherapy EO2463 from Cohorts 1 and 4 of the ongoing open label Phase I/II SIDNEY trial in patients with indolent non-Hodgkin lymphoma (iNHL), at the International Conference on Malignant Lymphoma (ICML) in Lugano.
      • In February 2025, Regeneron Pharmaceuticals announced that it has resubmitted the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company anticipates a decision from the FDA by the second half of 2025.
      • In February 2025, Eli Lilly announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for JAYPIRCA (pirtobrutinib), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a BTK inhibitor.

      What is Indolent Lymphoma?

      Indolent lymphoma is a slow-developing form of non-Hodgkin lymphoma that mainly involves B cells and can take several years to advance. Key subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL). Many individuals may experience no symptoms for extended periods, but common signs can include painless swollen lymph nodes, fatigue, night sweats, unintentional weight loss, and frequent infections. The precise cause is not fully understood, though potential risk factors include genetic mutations, immune system irregularities, chronic infections, or exposure to certain chemicals or radiation. Because it progresses slowly, indolent lymphoma is often carefully monitored, with treatment initiated only if symptoms escalate or the disease shows increased activity.

      Indolent Lymphoma Epidemiology Segmentation

      The indolent lymphoma epidemiology section provides insights into the historical and current indolent lymphoma patient pool and forecasted trends for the leading markets. The indolent lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

      • Total Incidence Cases of Indolent Lymphoma
      • Type-specific Cases of Indolent Lymphoma
      • Stage-specific Cases of Indolent Lymphoma
      • Total Treated Cases of Indolent Lymphoma

      Indolent Lymphoma Market Report Metrics

      Details

      Study Period

      2020–2034

      Indolent Lymphoma Market Report Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan].

      Indolent Lymphoma Epidemiology Segmentation

      Total Incidence Cases of Indolent Lymphoma, Type-specific Cases of Indolent Lymphoma, Stage-specific Cases of Indolent Lymphoma, and Total Treated Cases of Indolent Lymphoma

      Key Indolent Lymphoma Companies

      AstraZeneca, BeiGene, Xynomic Pharmaceuticals, Enterome, NovalGen, Eilean Therapeutics, Eli Lilly, Janssen Biotech, Pharmacyclics (an AbbVie company), Genmab, and others

      Key Indolent Lymphoma Therapies

      AZD0486, BGB-16673, Sonrotoclax + Zanubrutinib, Abexinostat, EO2463, NVG-111, ZE50-0134, JAYPIRCA, CALQUENCE, IMBRUVICA, EPKINLY, and others

      Scope of the Indolent Lymphoma  Market Report

      • Therapeutic Assessment: Indolent Lymphoma current marketed and emerging therapies
      • Indolent Lymphoma Market Dynamics: Key Market Forecast Assumptions of Emerging Indolent Lymphoma Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Indolent Lymphoma Market Access and Reimbursement

      Download the report to understand which factors are driving indolent lymphoma therapeutics market trends @ Indolent Lymphoma Market Trends

      Table of Contents

      1

      Indolent Lymphoma Market Key Insights

      2

      Indolent Lymphoma Market Report Introduction

      3

      Executive Summary

      4

      Key Events

      5

      Epidemiology and Market Forecast Methodology of Indolent Lymphoma

      6

      Indolent Lymphoma Market Overview at a Glance

      6.3

      Market Share (%) Distribution of Indolent Lymphoma by Therapies in 2024

      6.4

      Market Share (%) Distribution of Indolent Lymphoma by Therapies in 2034

      7

      Disease Background and Overview

      7.1

      Introduction

      7.2

      Indolent Lymphoma Signs and Symptoms 

      7.3

      Indolent Lymphoma Types

      7.4

      Indolent Lymphoma Classification

      7.5

      Indolent Lymphoma Causes

      7.6

      Indolent Lymphoma Stages

      7.7

      Indolent Lymphoma Diagnosis

      8

      Indolent Lymphoma Treatment

      9

      Epidemiology and Patient Population of Indolent Lymphoma

      9.1

      Key Findings

      9.2

      Assumptions and Rationale

      9.3

      Total Incident Cases of Indolent Lymphoma in the 7MM

      9.4

      The United States

      9.4.1

      Total Incidence Cases of Indolent Lymphoma in the United States

      9.4.2

      Types-specific Cases of Indolent Lymphoma in the United States

      9.4.3

      Stage-specific Cases of Indolent Lymphoma in the United States

      9.4.4

      Total Treated Cases of Indolent Lymphoma in the United States

      9.5

      EU4 and the UK

      9.6

      Japan

      10

      Patient Journey of Indolent Lymphoma

      11

      Marketed Indolent Lymphoma Therapies 

      11.1

      Key Competitors

      11.2

      JAYPIRCA (pirtobrutinib): Eli Lilly

      11.2.1

      Product Description

      11.2.2

      Regulatory Milestone

      11.2.3

      Other Development Activities

      11.2.4

      Summary of Pivotal Trials

      11.2.5

      Clinical Trials Information

      11.2.6

      Analyst Views

      11.3

      EPKINLY (epcoritamab-bysp): AbbVie/Genmab

      List to be continued in the report…

      12

      Emerging Indolent Lymphoma Therapies

      12.1

      Key Competitors

      12.2

      AZD0486: AstraZeneca

      12.2.1

      Product Description

      12.2.2

      Other Development Activities

      12.2.3

      Clinical Development

      12.2.3.1

      Clinical Trials Information

      12.2.4

      Safety and Efficacy

      12.2.5

      Analyst Views

      List to be continued in the report…

      13

      Indolent Lymphoma Market: Seven Major Market Analysis

      13.1

      Key Findings

      13.2

      Indolent Lymphoma Market Outlook

      13.3

      Conjoint Analysis

      13.4

      Key Indolent Lymphoma Market Forecast Assumption

      13.5

      Total Market Size of Indolent Lymphoma in the 7MM

      13.6

      Market Size of Indolent Lymphoma by Therapies in the 7MM

      13.7

      The United States Indolent Lymphoma Market Size

      13.7.1

      Total Market Size of Indolent Lymphoma in the United States

      13.7.2

      Market Size of Indolent Lymphoma by Therapies in the United States

      13.8

      EU4 and the UK Indolent Lymphoma Market Size

      13.9

      Japan Indolent Lymphoma Market Size

      14

      Unmet Needs of Indolent Lymphoma

      15

      SWOT Analysis of Indolent Lymphoma

      16

      KOL Views of Indolent Lymphoma

      17

      Indolent Lymphoma Market Access and Reimbursement

      18

      Bibliography

      19

      Indolent Lymphoma Market Report Methodology

      Related Reports

      Indolent Lymphoma Clinical Trial Analysis

      Indolent Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key indolent lymphoma companies, including AstraZeneca, BeiGene, Xynomic Pharmaceuticals, Enterome, NovalGen, Eilean Therapeutics, Eli Lilly, Janssen Biotech, Pharmacyclics (an AbbVie company), Genmab, among others.

      Non-Hodgkin's Lymphoma Market

      Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin's lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, among others.

      Follicular Lymphoma Market

      Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphoma Market companies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, among others.

      Marginal Zone Lymphoma Market

      Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MZL Market companies, including Celgene Corporation, AbbVie, Janssen Biotech, TG Therapeutics, Bayer, Roche Pharma, Gilead Sciences, Merck Sharp & Dohme, Cellectar Biosciences, Innovent Biologics, Bristol-Myers Squibb, Astrazeneca, Nordic Nanovector, AbbVie, InnoCare Pharma, Merck KGaA, ArQule, Merck, Verastem, Secura Bio, BeiGene, MEI Pharma, NantKwest, ImmunityBio, Loxo Oncology, Eli Lilly, TriSalus Life Sciences, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us
      Shruti Thakur
      [email protected]
      +14699457679
      www.delveinsight.com

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.